David K. Stone was appointed as a member of our Board of Directors in December 2011 and as our Chairman as of June 15, 2013. In 2006, Mr. Stone founded Liberty Tree Advisors, LLC, a life sciences investment banking and consulting firm where he is currently a Managing Director. Prior to this, from 2000 to 2006 Mr. Stone was a Managing Director and Partner at Flagship Ventures, a venture capital fund focused in the life sciences industry. From 1989 to 1999, Mr. Stone led the biotechnology equity research team at Cowen & Company. Mr. Stone is currently on the Board of Directors of PAKA Pulmonary Pharmaceuticals and of Seahorse Bioscience, where he is Chairman of the Audit Committee. From 2001 to 2009, he served on the Board of Directors of Oscient Pharmaceuticals, where he served as Chairman from 2005 to 2009.

Robert Coradini has served as a member of our Board of Directors since December 2011 and as our interim CEO as of June, 15 2013. Mr. Coradini currently serves as an expert to the medical device and biotechnology industry. Prior to this and since 1996 Mr. Coradini served in various executive capacities at several Johnson & Johnson (“J&J”) Companies. From June 2005 to May 2009, Mr. Coradini served as President of New Ventures for J&J Consumer Products Company which also included leading and growing OrthoNeutrogena (aka OrthoDermatologics), a leader in dermatology care, from January 2006 thru May 2009. From January 2003 through June 2005, Mr. Coradini served as President of CardioVations/Ethicon, a J&J Company involved with cardiac surgery and tissue management. From June 2000 to January 2003 Mr. Coradini was President of Lifescan, a J&J Company that provides medical devices to the diabetes market. Before Lifescan, Mr. Coradini was head of Business Development for J&J’s Medical Devices & Diagnostic Group and before that President of Cordis Endovascular. Prior to J&J, Mr. Coradini was with General Electric for ten years, seven of which were with GE Medical Systems. Mr. Coradini currently serves on the Board of Directors of WaferGen BioSystems and Chairs its Nominating and Governance Committee and is a member of its Compensation Committee.

Anne Egger was elected as a member of our Board of Directors in June 2009 and has been a consultant to the Company since March 2009. Ms. Egger has served as Vice President of Sales and Marketing of TopMD, a dermatology products company, since March 2012. Since March 2009, Ms. Egger has been the owner/director of AME Enterprises, LLC, a pharmaceutical consulting company. From October 1988 until her retirement in March of 2009, Ms. Egger served as head of the U.S. Sales and Marketing division of Galderma Laboratories, a joint venture between Nestlé and L’Oréal. Ms. Egger was also an Industry Adjunct member of the American Academy of Dermatology and a member of the American Society of Dermatologic Surgeons Industry.

Mark Fabiani was appointed as a member of our Board of Directors in December 2011. Mr. Fabiani is a Principal of Mark Fabiani LLC, a crisis management consulting firm, where he has served since 1997. Mr. Fabiani was formerly Special Counsel to President Clinton, Deputy Campaign Manager for Vice President Al Gore, and Deputy Assistant Attorney General at the Justice Department. Mr. Fabiani is an expert in public relations.

Mindy Meads was elected a member of our Board of Directors in April 2012. In October, 2012, Ms. Meads was appointed a Director of Wet Seal, Inc., a teen specialty retailer of fashionable and contemporary apparel and accessory items. Ms. Meads is an experienced CEO with 35 years of experience in the global apparel industry. From 2009 to 2011 she was the Co-CEO of Aeropostale Inc., a teen specialty retailer with more than 900 stores. From 2007 to 2009 she served as President and Chief Merchant Officer. In 2006 Ms. Meads was Chief Executive Officer and President of Victoria Secret Direct, an e-commerce and catalogue retailer. Prior to that, Ms. Meads was at Lands’ End from 1990 to 2005, serving as President and Chief Executive Officer from 2003 to 2005. She has held a variety of Senior Executive Merchandising roles with several leading retailers. She is a former Director of the Federal Reserve Bank for the 7th District, and sits on the board of several not-for profit companies. She currently serves on the Board of Trustees of The Masters School, and is a member of The Committee of 200, a business women’s leadership organization.

Kathryn Swintek, was elected to our Board of Directors, in April 2013. Since August 2010, Ms. Swintek has been a Managing Partner and member of the Investment Committee of Golden Seeds Fund 2, and Managing Director of Golden Seeds LLC, an angel investment forum backing women owned or managed early stage and growth companies. Prior to Golden Seeds, Ms. Swintek was a senior executive at BNP Paribas from November 1989 to April 2008, where she most recently served as Managing Director and Global Co-Head of its London-based Financial Sponsors Coverage Group. From 1974 to 1989, Ms. Swintek was a senior executive with Irving Trust Company (now known as BNY Mellon), where she was a Sr. Vice President and held positions in risk management, and acquisition finance, and managed business relationships for the International Division in North Africa and the Near East, as well as in France, where she served as Representative while residing in Paris. Ms. Swintek is Chair of the Governing Board and the Executive Committee of The Committee of 200, a business women’s leadership organization, which she joined in 2003. She serves on the Board of Directors of Trade Settlement, Inc., Turtle & Hughes, Inc., and Open Road Integrated Media, Inc. She is also a member of the Women’s Forum, Women Corporate Directors, and Women Business Leaders of the U.S. Health Care Industry Foundation. Ms. Swintek’s serves as the Chairperson of our Audit Committee.

LuAnn Via was elected to our Board of Directors in April 2012. In November 2012 Ms. Via became President and CEO of Christopher & Banks Corporation, a specialty retailer of women’s clothes; a company operating more than 600 retail stores. Prior to this, Ms. Via served as the President and Chief Executive Officer of Payless ShoeSource, a unit of Collective Brands, Inc., from July 2008 to October 2012 when the company was acquired and taken private. Before joining Payless ShoeSource, from January 2006 Ms. Via served as group divisional President of Lane Bryant and Cacique store chains and as President of Catherines stores, both divisions of Charming Shoppes, Inc. Prior to this, and for more than 20 years, Ms. Via held several leadership positions with a number of top retailers. Ms. Via is a Board member of Christopher & Banks Corporation and a member of The Committee of 200, a business women’s leadership group.

Robert Coradini
Interim CEO
Robert Coradini has served as a member of our Board of Directors since December 2011 and as our interim CEO as of June, 15 2013. Mr. Coradini currently serves as an expert to the medical device and biotechnology industry. Prior to this and since 1996 Mr. Coradini served in various executive capacities at several Johnson & Johnson (“J&J”) Companies. From June 2005 to May 2009, Mr. Coradini served as President of New Ventures for J&J Consumer Products Company which also included leading and growing OrthoNeutrogena (aka OrthoDermatologics), a leader in dermatology care, from January 2006 thru May 2009. From January 2003 through June 2005, Mr. Coradini served as President of CardioVations/Ethicon, a J&J Company involved with cardiac surgery and tissue management. From June 2000 to January 2003 Mr. Coradini was President of Lifescan, a J&J Company that provides medical devices to the diabetes market. Before Lifescan, Mr. Coradini was head of Business Development for J&J’s Medical Devices & Diagnostic Group and before that President of Cordis Endovascular. Prior to J&J, Mr. Coradini was with General Electric for ten years, seven of which were with GE Medical Systems. Mr. Coradini currently serves on the Board of Directors of WaferGen BioSystems and Chairs its Nominating and Governance Committee and is a member of its Compensation Committee.

Richard I. Steinhart
Senior Vice President – Finance; Chief Financial Officer and Treasurer
Richard Steinhart began serving as MELA Sciences’ Vice President, Finance, Chief Financial Officer, and Treasurer in April 2006, and Secretary in November 2006; in March 2012 he was promoted to Senior Vice President, Finance. Before joining the Company, he spent 14 years as Managing Director of Forest Street Capital/SAE Ventures, a boutique investment banking, venture capital, and management consulting firm focused on healthcare and technology companies. Prior to Forest Street Capital/SAE Ventures, he was Vice President and Chief Financial Officer of Emisphere Technologies, Inc.

Mr. Steinhart’s experience also includes seven years at CW Group, Inc., a venture capital firm focused on medical technology and biopharmaceutical companies, where he was a General Partner and Chief Financial Officer. Until December 2011, Mr. Steinhart served on the Board of Manhattan Pharmaceuticals, Inc., a biopharmaceutical company, and was Chairman of its Audit Committee. Mr. Steinhart began his career at Price Waterhouse, now known as PricewaterhouseCoopers. He holds BBA and MBA degrees from Pace University and is a Certified Public Accountant.

Dina Gutkowicz-Krusin
PhD, Principal Scientist and Director of Clinical Research
Dr. Gutkowicz-Krusin was one of the founders of MELA Sciences, Inc in 1990. Her responsibilities at MELA include: the development of data analysis and classification algorithms; designing studies for the research and development of products for review by FDA; preparation of scientific papers and regulatory submissions. Dr. Gutkowicz-Krusin received a BS in physics from the City College of New York and a PhD in theoretical physics from Cornell University, and was an NSF Postdoctoral Fellow at MIT.

Jeffrey Wallace
Senior Vice President, Development and Innovation
Jeffrey Wallace joined MELA Sciences in July of 2008 as a consultant before officially joining the company in April 2012 as the Senior Vice President of Research & Development and Operations. Jeff comes from a background of over 17 years in the medical industry as a leader in manual and automated software validation. Before joining the company, he worked as a Partner at SoftwareCPR, a company dedicated to providing regulatory support for the medical industry, and served as the President at ValidationCPR which is a company dedicated to bringing safe, effective and powerful life-enhancing medical devices to humanity.

Jeff began his career in the medical industry as a Quality Assurance Test Engineer at Baxter Healthcare where he worked for over nine years, focusing on the design and development of hardware, software, and user interfaces for automated test equipment. He has also demonstrated several leadership roles in managing projects to support the company in FDA inspection preparation and audits as well as software V&V plans, writing requirements, performing traceability analysis, work instructions, and technical protocols for operating software tools.

Prior to his career in healthcare, Jeff served in the United States Navy as an Aviation Electricians Mate for four years, performing the various function of an Aircraft Electrical Technician, P-3 Orion Aircraft Handler/Director and night shift supervisor. He holds his Bachelor’s Degree in Electronic Engineering Technology from ITT Technical Institute.

George M. Baskinger
Vice President, Quality Assurance and Regulatory Affairs
George Baskinger joined the MELA Sciences in 2009 as the Senior Director, Quality Assurance and Regulatory Affairs and as of January 2011 holds the position of Vice President, Quality Assurance and Regulatory Affairs. He has over 30 years experience in the pharmaceutical and medical device industries. George has previously held the positions as Director, Quality Assurance and Regulatory Affairs with Becton Dickinson and Company and prior to joining MELA Sciences, Vice President, Quality Assurance and Regulatory Affairs at Vyteris, Inc.  George’s experience also includes a position with the U.S. Food and Drug Administration as an Investigator and Biomedical Engineer. He holds a Bachelors Degree from Newark College of Engineering (NCE) and Masters Degree in Electrical Engineering from the New Jersey Institute of Technology (NJIT).

Nyq Kabelev
Vice President, Research & Development
Nyq Kabelev has served as Vice President of Research & Development since January 2008. Nyq, who joined the Company in 1999, previously held the positions of Computer Scientist, Director of Algorithm and Software Development, and MelaFind^® Project Team Leader. Prior to his time at MELA Sciences, Nyq worked at the Center for Telecommunication Research at Columbia University.  He holds a BS degree in Computer Science from Transport and Telecommunication Institute (Riga Aviation University), Latvia.